Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates
- 10 March 2015
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy Clinical Development
- Vol. 26 (2) , 113-124
Abstract
No treatment is available for early-onset forms of metachromatic leukodystrophy (MLD), a lysosomal storage disease caused by autosomal recessive defect in arylsulfatase A ( ARSA ) gene causing severe demyelination in central and peripheral nervous systems. We have developed a gene therapy approach, based on intracerebral administration of AAVrh.10-hARSA vector, coding for human ARSA enzyme. We have previously demonstrated potency of this approach in MLD mice lacking ARSA expression. We describe herein the preclinical efficacy, safety, and biodistribution profile of intracerebral administration of AAVrh.10-hARSA to nonhuman primates (NHPs). NHPs received either the dose planned for patients adjusted to the brain volume ratio between child and NHP (1×dose, 1.1×10 11 vg/hemisphere, unilateral or bilateral injection) or 5-fold this dose (5×dose, 5.5×10 11 vg/hemisphere, bilateral injection). NHPs were subjected to clinical, biological, and brain imaging observations and were euthanized 7 or 90 days after injection. There was no toxicity based on clinical and biological parameters, nor treatment-related histological findings in peripheral organs. A neuroinflammatory process correlating with brain MRI T2 hypersignals was observed in the brain 90 days after administration of the 5×dose, but was absent or minimal after administration of the 1×dose. Antibody response to AAVrh.10 and hARSA was detected, without correlation with brain lesions. After injection of the 1×dose, AAVrh.10-hARSA vector was detected in a large part of the injected hemisphere, while ARSA activity exceeded the normal endogenous activity level by 14–31%. Consistently with other reports, vector genome was detected in off-target organs such as liver, spleen, lymph nodes, or blood, but not in gonads. Importantly, AAVrh.10-hARSA vector was no longer detectable in urine at day 7. Our data demonstrate requisite safe and effective profile for intracerebral AAVrh.10-hARSA delivery in NHPs, supporting its clinical use in children affected with MLD.Keywords
This publication has 38 references indexed in Scilit:
- Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic LeukodystrophyScience, 2013
- Neurodevelopmental Outcomes of Umbilical Cord Blood Transplantation in Metachromatic LeukodystrophyTransplantation and Cellular Therapy, 2013
- The natural course of gross motor deterioration in metachromatic leukodystrophyDevelopmental Medicine & Child Neurology, 2011
- Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literatureBone Marrow Transplantation, 2010
- Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic optionsActa Paediatrica, 2008
- Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in miceJournal of Clinical Investigation, 2006
- Enzyme Replacement for Lysosomal DiseasesAnnual Review of Medicine, 2006
- Lysosomal sulfatide storage in the brain of arylsulfatase A-deficient mice: cellular alterations and topographic distributionActa Neuropathologica, 2004
- Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cellsJournal of Clinical Investigation, 2004
- Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndromeCurrent Opinion in Hematology, 1999